FPC
JAZZ icon

Falcon Point Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Falcon Point Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,204
Closed -$388K – 127
2015
Q2 		$388K Sell
2,204
-247
-10% -$44.4K 0.13% 95
2015
Q1 		$424K Hold
2,451
– – 0.33% 88
2014
Q4 		$401K Sell
2,451
-1,297
-35% -$215K 0.37% 88
2014
Q3 		$602K Buy
+3,748
New +$576K 0.51% 77

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Falcon Point Capital's JAZZ Position: Q3 2015 in Review

Falcon Point Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2015, closing a stake of 2,204 shares — an estimated $388K sold.

Falcon Point Capital first reported a position in JAZZ in Q3 2014 and held it in 4 quarters. The position peaked at $602K in Q3 2014. 360 funds tracked by Wall St. Rank hold JAZZ as of Q3 2015.

  • Falcon Point Capital reported no remaining Jazz Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Falcon Point Capital sold 2,204 Jazz Pharmaceuticals shares in Q3 2015, an estimated $388K.
  • Falcon Point Capital first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Falcon Point Capital's Jazz Pharmaceuticals position peaked at $602K in Q3 2014.
  • 360 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2015.

Based on Falcon Point Capital's 13F filing for Q3 2015, filed 20 Oct 2015.